Intravenous thrombolytic therapy for acute ischemic stroke: Weighing the risks and benefits of tissue plasminogen activator

Postgraduate Medicine

Volumn 103, Issue 4, 1998, Pages 221-231

  Koller, Richard L ^a   Anderson, David C ^b  

^a Koller Clinic of Neurology   (United States)

^b HENNEPIN COUNTY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE;

BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; FIBRINOLYTIC THERAPY; HUMAN; INTENSIVE CARE; INTRAVENOUS DRUG ADMINISTRATION; REVIEW; RISK BENEFIT ANALYSIS;

EID: 0031979949     PISSN: 00325481     EISSN: None     Source Type: Journal    
DOI: 10.3810/pgm.1998.04.457     Document Type: Review

References (10)

1. EMS Bridging Trial Investigators. Combined intravenous/intra-arterial thrombolytic therapy: safety, time-to-treatment, and frequency of clot. (Abstr) Stroke 1996; 27(1):165
2. del Zoppo GJ, Higashida RT, Furlan AJ, et al. The prolyse in acute cerebral thromboembolism trial (PROACT): results of 6 mg dose tier. Stroke 1998;29(1):4-11
3. Multicentre Acute Stroke Trial-Europe Study Group. Thrombolytic therapy with streptokinase in acute ischemic stroke. N Engl J Med 1996;335(3):145-50
4. Multicentre Acute Stroke Trial-Italy (MAST-I) Group. Randomised controlled trial of streptokinase, aspirin, and combination of both in treatment of acute ischaemic stroke. Lancet 1995;346(8989):1509-14
5. Australian Streptokinase (ASK) Trial Study Group. Streptokinase for acute ischemic stroke with relationship to time of administration. JAMA 1996;276(12):961-6
6. Hacke W, Kaste M, Fieschi C, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). JAMA 1995;274(13):1017-25
7. National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995;333(24):1581-7
8. Levy DE, Brott TG, Haley EC Jr, et al. Factors related to intracranial hematoma formation in patients receiving tissue-type plasminogen activator for acute ischemic stroke. Stroke 1994;25(2):291-7
9. Adams HP Jr, Brott TG, Furlan AJ, et al. Guidelines for thrombolytic therapy for acute stroke: a supplement to the guidelines for the management of patients with acute ischemic stroke. A statement for healthcare professionals from a Special Writing Group of the Stroke Council, American Heart Association. Stroke 1996; 27(9):1711-8
10. Practice advisory: thrombolytic therapy for acute ischemic stroke: summary statement. Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 1996;47(3):835-9